66 unknown, 29 recruiting, 14 completed, 11 not yet recruiting. 103 Phase 2, 30 Phase 1, 12 Phase 3, 6 Not applicable, 1 Early Phase 1.
Follow Chidamide: new trials by email Literature Review of Chidamide trials Research Report on Chidamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes Chidamide - Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 15 | 2026-07-01 | 2026-06-01 |
| Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Chidamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Rong Tao | 69 | 2026-06-16 | 2026-06-18 |
| An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. Azacitidine (AZA) - Peripheral T-Cell Lymphoma Refractory | Early Phase 1 | Recruiting | Second Affiliated Hospital of Soochow University | 30 | 2026-06-01 | 2026-05-20 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma Lisaftoclax, Chidamide, rituximab - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-22 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Chidamide, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Ou Bai, MD/PHD | 50 | 2026-04-30 | 2026-03-25 |
| Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy Chidamide, radiotherapy - Head and Neck Squamous Cell Carcinoma HNSCC | Phase 1 | Recruiting | West China Hospital | 6 | 2026-04-23 | 2026-04-28 |
| Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL Polatuzumab Vedotin, Rituximab (R), Chidamide - Double Expressor DLBCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 68 | 2026-04-01 | 2026-02-17 |
| Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Chidamide, Toripalimab, Anlotinib - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-03-31 | 2026-03-20 |
| Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma Chidamide, Sintilimab, Bevacizumab - Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Phase 2 | Recruiting | Sun Yat-sen University | 34 | 2026-03-27 | 2026-04-08 |
| PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL PD-1 antibody, radiotherapy, Chidamide - Natural Killer/T-cell Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 47 | 2026-03-01 | 2026-03-20 |
| CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL Chidamide, Rituximab, Polatuzumab Vedotin - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 58 | 2026-02-03 | 2026-07-29 |
| EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas Zeprumetostat, Golidocitinib, Chidamide - Mature T-cell and NK-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-01-01 | 2026-01-14 |
| Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor Dalpiciclib, Chidamide, Enitinostat - HR+/HER2- Advanced Breast Cancer | Phase 2 | Not yet recruiting | Beijing 302 Hospital | 155 | 2025-10-01 | 2025-08-13 |
| Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Linperlisib, Chidamide - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 54 | 2025-09-15 | 2025-08-24 |
| Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML Chidamide - Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2025-09-01 | 2025-12-26 |
| Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients VEN (Venetoclax), Azacitidine (AZA), Chidamide - Adult T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 27 | 2025-09-01 | 2026-10-16 |
| Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 101 | 2025-08-27 | 2025-12-31 |
Showing 20 of 127. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (18) · Lymphoma, Large B-Cell, Diffuse (14) · Recurrence (8) · Breast Neoplasms (7) · Leukemia, Myeloid, Acute (7) · Lymphoma, Non-Hodgkin (6) · Immunoblastic Lymphadenopathy (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Colorectal Neoplasms (3) · Lymphoma (3) · Lymphoma, T-Cell (3) · Neoplasms, Experimental (3) · Carcinoma, Neuroendocrine (2)
Sun Yat-sen University (16) · Chipscreen Biosciences, Ltd. (7) · Peking Union Medical College Hospital (6) · Ruijin Hospital (6) · Sichuan University (6) · The First Affiliated Hospital of Soochow University (6) · Chinese PLA General Hospital (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · Tianjin Medical University Cancer Institute and Hospital (5) · Nanfang Hospital, Southern Medical University (4) · The First Affiliated Hospital with Nanjing Medical University (4) · Beijing 302 Hospital (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Chinese Academy of Medical Sciences (3) · Peking University (3)
China (112) · Taiwan (5) · Thailand (1)
Chia-Nan Chen, Ph.D. (2) · Chunmei Bai, M.D. (2) · Li Zhang (2) · Mei Dong (2) · Ou Bai, PHD (2) · Susen Wang, MD (2) · Ting Liu, MD (2) · Yanyan Liu, M.D. Ph.D (2) · Binghe Xu (1) · Bingzong LI (1) · Bingzong Li, Professor (1) · Biyun Wang (1) · Caicun Zhou (1) · Caigang Liu, doctoral (1) · Daobin Zhou, M.D (1)
PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 22851565, PMID 24721323, PMID 25652253, PMID 25712263, PMID 27717585, PMID 30209556, PMID 31036468, PMID 31724191, PMID 32299513, PMID 33097085, PMID 34398971, PMID 35170082, PMID 35659479, PMID 37488286, PMID 38438735, PMID 38805037, PMID 39093981, PMID 39229263, PMID 39468701, PMID 40802906, PMID 41080407, PMID 41366419, PMID 41428995, PMID 42124356, PMID 42827632